Stockreport
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
Last mimedx group, inc earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: phx.corporate-ir.net/phoenix.zhtml?c=213465&p=irol-irhome
MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company’s Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit®-Wound Gel kits, developed by Antoine Turzi and approved by FDA in 2022, are covered nationally by CMS and LCD for the treatment of diabetic chronic wounds under HCPCS code G0465. “With the addition of RegenKit, we are continuing to br
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MDXG | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MDXG alerts
MDXG alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDXG alerts
High impacting MiMedx Group, Inc news events
Weekly update
A roundup of the hottest topics
MDXG
NEWS
NEWS
- MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel [Yahoo! Finance][Yahoo! Finance]
- With 47% stake, MiMedx Group, Inc. (NASDAQ:MDXG) seems to have captured institutional investors' interest [Yahoo! Finance][Yahoo! Finance]
- MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro [Yahoo! Finance][Yahoo! Finance]
- MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro[GlobeNewswire]
- MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Mizuho from $12.00 to $10.00. They now have an "outperform" rating on the stock.[MarketBeat]
- More
MDXG
SEC Filings
SEC Filings
- 11/10/25 - Form 4
- 11/6/25 - Form 144
- 10/29/25 - Form 8-K
- MDXG's page on the SEC website
- More